Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study on Persistence on Certolizumab and Predictors Thereof in with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial-Spondyloarthritis Patients: Biopure Registry (The BIOlogic aPUlian REgistry)

Trial Profile

Study on Persistence on Certolizumab and Predictors Thereof in with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial-Spondyloarthritis Patients: Biopure Registry (The BIOlogic aPUlian REgistry)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Apr 2019 Results assessing the the effectiveness of certolizumab and identify any predictors of favorable outcome in patients with RA, PsA, or SpA (n=355) published in the Clinical Drug Investigation
    • 15 Jul 2018 New trial record
    • 16 Jun 2018 Results (n=345) assessing Drug Survival on Certolizumab, presented at the 19th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top